Researchers to study depression in AMD patients

Age-related Macular Degeneration (AMD) is the leading cause of vision loss in Americans 60 years of age and older. It gradually destroys sharp, central vision, which is needed for seeing objects clearly and for common daily tasks such as reading and driving. AMD affects the macula, the part of the eye that allows you to see fine detail. In some cases, the disease advances so slowly that people notice little change in their vision. In others, it progresses faster and may lead to a loss of vision in both eyes

Medical News Today reports that researchers at the Farber Institute for Neurosciences at Thomas Jefferson University and the Department of Psychiatry and Human Behavior at Jefferson Medical College of Thomas Jefferson University were recently awarded a $3.7 million grant from The National Eye Institute to study depression in patients diagnosed with age-related macular degeneration.

During the trial, called the Low Vision Depression Prevention Trial, researchers will test a combined treatment to prevent depression and disability associated with AMD. They will also test the efficacy of a low vision rehabilitation and psychological intervention program designed to treat/prevent depression in patients diagnosed with the disease by helping them maintain their independence and participation in enjoyable activities.